| Objective：A retrospective analysis of factors failed previous treatment of advanced gastriccancer and accept third-line chemotherapy in patients with clinical data, to understandthe clinical efficacy of third-line chemotherapy for advanced gastric cancer, safetyand impact on clinical efficacyMethods：ALL patients were divided into three groups:①Irinotecan group of23patients:irinotecan monotherapy or irinotecan and fluorouracil chemotherapy drugs②Docetaxel group of21patients:Docetaxel monotherapy or irinotecan and fluorouracilchemotherapy drugs③The last group of20cases:give symptomatic and supportivetreatment。Results：Of64patients were eligible for analysis.，Median PFS was2.0months in theirinotecan group and2.3months in the paclitaxe group P=0.691。Median OS was5.4months in the irinotecan group and5.6months in the paclitaxe group P=0.828。Median PFS was2.0months in the Chemotherapy group (irinotecan group+paclitaxe group)and1.1months in the best support group P<0.001。Median OS was5.5months in the Chemotherapy group (irinotecan group+paclitaxe group)and3.2months in the best support group P<0.001. Response rate was9.5%in thepaclitaxel group and4.3%in the irinotecan group.Common grade3to4adverseevents were Diarrhea (irinotecan group,21.7%; paclitaxel group,4.7%, P=0.047),Irinotecan group and docetaxel group the incidence of severe alopecia were4.3%,42.8%, P=0.008Conclusions：1. Three-line chemotherapy for advanced gastric cancer compared with bestsupportive treatment RR, PFS, OS are benefited. 2. PS score and PFS after first-line chemotherapy is an important factoraffecting the prognosis of patients3. Irinotecan more docetaxel high incidence of diarrhea, but no significantdifference；Irinotecan more high incidence of diarrhea docetaxel, but lower in thesevere hair loss occurs4. No statistically significant difference was observed between Irinotecan-containing group and docetaxel-containing group for OS and PFS.,toxicity can betolerated... |
PDF Full Text Request